Sanofi US
Cambridge
Massachusetts
United States
196 articles with Sanofi US
-
Sanofi and Regeneron’s Dupixent (dupilumab) met its primary and all secondary endpoints in the Phase III BOREAS trial, significantly reducing severe exacerbations in COPD.
-
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
3/13/2023
Provention Bio, Inc. today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions.
-
Sen. Bernie Sanders (I-VT), chairman of the Senate’s Health, Education, Labor and Pensions Committee, sent a letter to Sanofi and Novo Nordisk urging them to lower insulin prices.
-
The FDA approved Sanofi and Sweden-based Sobi’s efanesoctocog alfa, now marketed as Altuviiio, to treat bleeding in adults and children with hemophilia A.
-
Glooko Announces Global Collaboration with Sanofi for SoloStar® Pen Connectivity with New Device SoloSmart®
2/23/2023
Glooko Inc. ("Glooko"), today announced that they have entered into a partnering agreement with Sanofi to increase their support of people living with diabetes and healthcare professionals, by integrating SoloSmart with the Glooko® platform.
-
The FDA accepted the BLA for and granted Pfizer's maternal RSV vaccine candidate priority review.
-
Sanofi’s global head of R&D, John Reed, is leaving his position to pursue another opportunity outside the company, the French multinational announced Monday.
-
Sanofi is discontinuing its Phase III study of tolebrutinib, an investigational BTK inhibitor for myasthenia gravis.
-
Sanofi licensed CytoReason's inflammatory bowel disease model in a multi-million dollar bid to identify new therapies for IBD and Crohn’s and colitis.
-
Sanofi Selects THREAD as Global Decentralized Clinical Trials Provider
1/17/2023
THREAD , the leading technology and consulting service provider enabling electronic clinical outcome assessments (eCOA) and decentralized clinical trials (DCTs), announced today its five-year collaboration with innovative global health care company, Sanofi.
-
Amgen’s Repatha may cause cardiac harm, according to a reassessment of the biologic’s late-stage trial data.
-
Sanofi and Innate Pharma expand their longtime collaboration by licensing up to three NK cells engager programs in cancer immunotherapy valued at more than $1.4 billion.
-
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
12/16/2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults and adolescents with eosinophilic esophagitis (EoE).
-
The FDA greenlit Libtayo plus chemotherapy to treat patients with advanced NSCLC irrespective of EGFR, ALK or ROS1 aberrations. It is the drug’s second approval in this space.
-
Sanofi entered into a partnership with Insilico Medicine to develop drugs for up to six targets. The deal is worth a potential $1.2 billion.
-
Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
11/8/2022
Insilico Medicine, a clinical stage artificial intelligence -driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi.
-
The implications of the Inflation Reduction Act of 2022 (IRA) are beginning to show as Alnylam drops the Stargardt indication for vutrisiran and Sanofi's CEO reassures investors.
-
Provention Bio entered a co-promotion agreement with Sanofi ahead of the possible November approval of teplizumab. If approved, the drug would be the first approved to modify T1D.
-
Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
10/6/2022
Sanofi US to co-promote teplizumab, adding it to its current commercial activities in diabetes care, leveraging its existing best-in-class customer-facing field teams Provention Bio, Inc. retains all rights to teplizumab Commercialization activities are dependent on U.S. FDA approval of teplizumab, potentially on November 17, 2022.
-
Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
10/6/2022
Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has entered into a co-promotion agreement with Sanofi U.S. for the launch of Provention's lead investigational drug candidate teplizumab.